Evidence is mounting that circulating tumor deoxyribonucleic acid can be tested accurately, frequently, and in a noninvasive form. Its role in monitoring patients with cancer, particularly colorectal cancer, is increasing. In this brief review, we discuss its current role when measured using next-generation sequencing-based methods.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888803PMC
http://dx.doi.org/10.1055/s-0044-1801755DOI Listing

Publication Analysis

Top Keywords

next-generation sequencing-based
8
circulating tumor
8
colorectal cancer
8
current issues
4
issues next-generation
4
sequencing-based circulating
4
tumor dna
4
dna analysis
4
analysis colorectal
4
cancer evidence
4

Similar Publications

Current Issues of Next-Generation Sequencing-Based Circulating Tumor DNA Analysis in Colorectal Cancer.

South Asian J Cancer

October 2024

Clinical Services and Specialist Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Evidence is mounting that circulating tumor deoxyribonucleic acid can be tested accurately, frequently, and in a noninvasive form. Its role in monitoring patients with cancer, particularly colorectal cancer, is increasing. In this brief review, we discuss its current role when measured using next-generation sequencing-based methods.

View Article and Find Full Text PDF

Genetic characterization including Southern blot analysis of recombinant Chinese hamster ovary (CHO) cell lines expressing biologics is an essential prerequisite for regulatory submissions. The transposon-based expression system for CHO cell lines enables the insertion of DNA sequences into the genome and has been widely used by the biopharmaceutical industry. The system yields clones that are both highly productive and genetically stable.

View Article and Find Full Text PDF

Background: The microbiome is crucial for many physiological processes, including immunity, metabolism, and reproduction.

Aims: This review aims to contribute to a detailed understanding of the microbiome of the genital tract, which can lead to better management of dysbiosis and reproductive disorders.

Methods: Data from the four international information databases Medline, Scopus, Embase, and Google Scholar.

View Article and Find Full Text PDF

DNA methylation of tumor suppressor genes in cancer is known to be a mechanism for silencing gene expression, but much remains unknown about its extent and relationship to somatic variants at the DNA sequence level. In this study, we comprehensively analyzed DNA methylation and somatic variants of all gene regions across the genome of the major tumor suppressor genes, , , , and mismatch repair genes in colorectal cancer using a novel next-generation sequencing-based analysis method. The Targeted Methyl Landscape (TML) shows that DNA hypermethylation patterns of these tumor suppressor genes in colorectal cancer are more complex and widespread than previously thought.

View Article and Find Full Text PDF

Non-invasive prenatal testing for dominant single-gene disorders using targeted next-generation sequencing.

QJM

February 2025

Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China.

Background: Current noninvasive prenatal testing (NIPT) based on cell-free DNA (cfDNA) mainly targets the detection of chromosome aberrations but not dominant single-gene disorders (dSGDs).

Aim: This prospective pilot study aims to evaluate the clinical utility of a plasma cfDNA and targeted next-generation sequencing-based NIPT approach for dSGDs (NIPT-dSGD), with a particular focus on neurodevelopmental disorders (NDDs).

Methods: The NIPT-dSGD method targeted 34 genes, including 25 correlated to NDDs and nine correlated to Noonan spectrum, skeletal, craniosynostosis, and other syndromic disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!